These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 15878055

  • 1. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR.
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P.
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [Abstract] [Full Text] [Related]

  • 3. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ.
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [Abstract] [Full Text] [Related]

  • 4. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.
    Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL.
    Ophthalmology; 2009 Apr; 116(4):797-801. PubMed ID: 19344827
    [Abstract] [Full Text] [Related]

  • 5. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
    Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, Fluocinolone Acetonide Uveitis Study Group.
    Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
    [Abstract] [Full Text] [Related]

  • 6. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
    Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR.
    J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
    [Abstract] [Full Text] [Related]

  • 7. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS.
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [Abstract] [Full Text] [Related]

  • 8. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D.
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [Abstract] [Full Text] [Related]

  • 9. Treatment of ocular inflammatory disorders with daclizumab.
    Papaliodis GN, Chu D, Foster CS.
    Ophthalmology; 2003 Apr; 110(4):786-9. PubMed ID: 12689903
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, AIN457A2208 Study Group.
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [Abstract] [Full Text] [Related]

  • 11. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS.
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [Abstract] [Full Text] [Related]

  • 12. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE.
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT.
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [Abstract] [Full Text] [Related]

  • 14. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.
    JAMA Ophthalmol; 2017 Jun 01; 135(6):511-518. PubMed ID: 28426849
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J.
    Eye (Lond); 2005 Aug 01; 19(8):841-5. PubMed ID: 15389273
    [Abstract] [Full Text] [Related]

  • 16. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Research GroupOcular Inflammation Service, The University of Pennsylvania, Philadelphia, Philadelphia, PA 19104, USA., Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE.
    Ophthalmology; 2011 Oct 01; 118(10):1916-26. PubMed ID: 21840602
    [Abstract] [Full Text] [Related]

  • 17. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ.
    Ocul Immunol Inflamm; 2007 Oct 01; 15(2):63-70. PubMed ID: 17558830
    [Abstract] [Full Text] [Related]

  • 18. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents.
    Walton RC, Nussenblatt RB, Whitcup SM.
    Ophthalmology; 1998 Nov 01; 105(11):2028-34. PubMed ID: 9818601
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F.
    Rheumatology (Oxford); 2007 Jul 01; 46(7):1161-4. PubMed ID: 17478466
    [Abstract] [Full Text] [Related]

  • 20. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD.
    Ophthalmology; 2018 Jul 01; 125(7):1075-1087. PubMed ID: 29429764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.